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 1 
INTRODUCTION 
 
Diabetes mellitus is a common endocrine disorder which involves 
multiple organ systems and leads to significant morbidity and mortality 
due to accompanying complications. Diabetes mellitus has been defined 
as "A metabolic syndrome characterised by chronic hyperglycaemia and 
disturbance of carbohydrate, fat and protein metabolism associated with 
absolute or relative deficiency in insulin secretion and or insulin 
action".The metabolic dysregulation associated with DM causes 
secondary pathophysiologic changes in multiple organ systems that 
impose a tremendous burden on the individual with diabetes and on the 
health care system.  
Much has been accomplished in the field of diabetes and what has 
been troubling everyone is the large macrovascular and micro vascular 
complications of diabetes involving kidneys, eyes, blood vessels, nerves 
and heart. 
Thyroid diseases are also a common endocrinopathy seen in the 
adult population. Thyroid hormones are intimately involved in cellular 
metabolism. 
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Thus excess or deficit of either insulin or thyroid hormones could 
result in the functional derangement of the cellular metabolism. 
The present work is a modest attempt to study the prevalence of 
thyroid disorders in patients with type 2 diabetes mellitus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS  
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AIM OF THE STUDY 
 
1. To study the prevalence of thyroid disorders in patients with type 2 
diabetes mellitus. 
2. To study the distribution of thyroid disorders in patients with type 
2 diabetes mellitus regarding age, sex, duration of diabetes, family 
history, regularity of treatment and BMI. 
3. To evaluate the relationship between glycemic control and 
occurrence of altered thyroid function in type 2 diabetes mellitus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF 
LITERATURE  
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REVIEW OF LITERATURE 
 
Diabetes mellitus is characterised by chronic hyperglycemia with 
disturbances of carbohydrate, fat, and protein metabolism resulting from 
defects in insulin secretion, insulin action, or both.1  
 
PROBLEM STATEMENT 
In the first edition of the IDF Diabetes Atlas, released in 2000, the 
estimated global diabetes prevalence was 151 million. Now the estimated 
diabetes prevalence for 2010 has risen to 285 million, representing 6.4% 
of the world’s adult population, with a prediction that by 2030 the 
number of people with diabetes will have risen to 438 million. Far from 
being a disease of higher income nations, diabetes is very much a disease 
associated with poverty and disproportionately affecting the lower socio-
economic groups3. Although the prevalence of both type 1 and type 2 DM 
is increasing worldwide, the prevalence of type 2 DM is rising much 
more rapidly because of increasing obesity and reduced activity levels as 
countries become more industrialised. Previously a disease of the middle 
aged and elderly, type 2 diabetes has recently escalated in all age groups 
and is now being seen in younger age groups.4 
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Unfavourable modification of lifestyle and dietary habits with 
urbanisation are the most important factors for the development of 
diabetes. The percentage of diabetic cases in urban areas is projected to 
increase from 54% in 1995 to 73% by the year 2025.5 According to IDF 
(2009), India has the highest number of people suffering from diabetes 
mellitus with 50.8 million and spends 2.8 billionUS$ or 1% of the global 
health expenditure for diabetes and related problems6. United Nations in 
2006 in Resolution 61/225 stated that “diabetes is a chronic, debilitating 
and costly disease associated with severe complications, which poses 
severe risks for families, Member States and the entire world”.7 
 
HISTORY 
Diabetes is as old as medicine. Early evidence of description of 
symptoms of diabetes recorded in the Ebers papyrus, 1550 B.C.8 Arateus 
(30-90 AD), coined the term diabetes, meaning “siphon,” to explain the 
“liquefaction of the flesh and bones into urine”. In Greek this word means 
'to run through' that describes 'unquenchable thirst' seen in association 
with this disease.9 Shushruta (Circa 600AD) noted this disease in 
Ayurveda and described it as "Madhumeha".10 
In 1869, Paul Langerhans, published in his dissertation on 
pancreatic histology described “clumps of cells,” which were named the 
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islets of Langerhans shortly after his death.11,12  In 1889, Minkowski and 
Von Mering, in Strassburg, Germany, discovered the central role of the 
pancreas in diabetes.13 In 1910, Jean de Meyer suggested that the 
pancreatic secretion lacking in diabetic state to be called as “Insulin” to 
denote it’s origin from insulae of Langerhans.14 Banting and Charles Best 
in 1921, extracted insulin from dog's pancreas.15 The first chemical 
application of insulin was on 14 year old Leon and Thompson, a patient 
of diabetic ketoacidosis in January 1922 in Canada. This discovery 
revolutionized the management of diabetes. Oral hypoglycaemic drugs 
were introduced by Frank and Fuchs in 1955.8 
 
DESCRIPTION OF DIABETES MELLITUS 
When fully expressed, diabetes is characterized by fasting 
hyperglycemia, but the disease can also be recognized during less overt 
stages, most usually by the presence of glucose intolerance. Diabetes may 
present with characteristic symptoms such as thirst, polyuria,blurring of 
vision,weight loss and polyphagia.Hyperglycemia sufficient to cause 
pathologic functional changes may quite often be present for a long time 
before the diagnosis is made.1 Patients may revert to having impaired 
glucose regulation or even normal glycemia, particularly in recent-onset 
type 2 diabetes.16 
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In type 1 diabetes, after a short period of insulin treatment, there 
may be a variable period when insulin is no longer required for survival 
and glucose tolerance may improve, the so-called honeymoon period. 
Eventually such patients do need insulin treatment for survival.17 
Etiologic Classification of diabetes mellitus2 
I. Type 1 diabetes 
A. Immune mediated 
B. Idiopathic 
 
II. Type 2 diabetes 
III. Other specific types 
A. Genetic defects of b - cell function 
B. Genetic defects in insulin action 
C. Diseases of the exocrine pancreas 
D. Endocrinopathies 
E. Drug - or chemical induced 
F. Infections 
G. Uncommon forms of immune-mediated diabetes 
H. Other genetic syndromes sometimes associated with diabetes 
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IV. Gestational diabetes mellitus (GDM) 
The majority of cases of diabetes fall into two broad 
etiopathogenetic categories, now called type 1 and type 2 diabetes. 
 
TYPE 1 DIABETES MELLITUS 
Type 1 diabetes is the form of the disease due primarily to β-cell 
destruction in which insulin is required for survival. It is characterized by 
the presence of anti-GAD, anti-islet cell, or antiinsulin antibodies, which 
reflects the autoimmune processes that have led to β-cell destruction.18,19 
 
TYPE 2 DIABETES MELLITUS 
Type 2 diabetes is the most common form of diabetes. Insulin 
resistance and abnormal insulin secretion are central to the development 
of type 2 DM.2 Patients with type 2 diabetes usually have insulin 
resistance and relative, rather than absolute, insulin deficiency and are 
associated with progressive β-cell failure with increasing duration of 
diabetes20  The risk of developing type 2 diabetes increases with age, 
obesity, physical inactivity and family history of diabetes.1 The disease 
can occur at any age and is now seen in children and adolescents.21 
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DIAGNOSTIC CRITERIA FOR DIABETES MELLITUS22  
Symptoms of diabetes plus random plasma glucose concentration 
200 mg/dl (11.1 mmol/l). Random is defined as any time of day without 
regard to time since last meal. The classic symptoms of diabetes include 
polyuria, polydipsia and unexplained weight loss    (or)  
FPG 26 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake 
for at least 8 hours.        (or)  
2 hours post load glucose 200 mg/dl (11.1 mmol/l) during an 
OGTT. The test should be performed as described by WHO, using a 
glucose load containing the equivalent of 75 gm anhydrous glucose 
dissolved in water. 
In the absence of unequivocal hyperglycaemia these criteria should 
be confirmed by repeat testing on a different day. FPG is the most reliable 
and convenient test for identifying DM in asymptomatic individuals. 
HbA1C is not currently recommended to diagnosis of diabetes. 
 
IMPAIRED GLUCOSE TOLERANCE1 
Defined as 2 hours values in the oral glucose tolerance test (OGTT) 
between 140 and 199mg/dl (7.8 and 11.1 mmol/L). Glucose tolerance is 
above the conventional normal range but lower than the level diagnostic 
of diabetes. Persons with IGT have a high risk of developing diabetes and 
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arterial disease. IGT is more frequent in obese persons and often is 
associated with hyperinsulinemia and insulin resistance. 
 
IMPAIRED FASTING GLUCOSE1 
Defined as fasting plasma glucose concentrations of 100 to 125 
mg/dL (5.6 to <7.0 mmol/L). IFG is also a stage of impaired glucose 
homeostasis with fasting glucose levels were above normal but below 
those diagnostic for diabetes. 
 
ACUTE COMPLICATIONS OF DM2 
Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar 
state (HHS) are acute complications of diabetes. DKA primarily occurs in 
type 1 DM but, can also occur in type 2 DM. HHS is primarily seen in 
individuals with type 2 DM. Both disorders are associated with absolute 
or relative insulin deficiency, volume depletion, and acid-base 
abnormalities. 
 
CHRONIC COMPLICATIONS OF DM2 
The vascular complications of DM are divided into microvascular 
(retinopathy, neuropathy, nephropathy) and macrovascular complications 
[coronary artery disease (CAD), peripheral arterial disease (PAD), 
cerebrovascular disease]. Nonvascular complications include problems 
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such as gastroparesis, infections, and skin changes. The microvascular 
complications of both type 1 and type 2 DM result from chronic 
hyperglycemia. Evidence implicating a causative role for chronic 
hyperglycemia in the development of macrovascular complications were 
inconclusive. Other factors (dyslipidemia and hypertension) also play 
important roles in macrovascular complications. 
 
DYSLIPIDEMIA IN DIABETES 
The dyslipidemia in type 2 diabetes and insulin resistance typically 
consists of elevated triglycerides and decreased HDL cholesterol level23 
and of qualitative abnormality in the LDL structure, i.e., decreased size 
and increased density of the LDL particle. 
 
METABOLIC SYNDROME AND OBESITY25 
The metabolic syndrome (syndrome X, insulin resistance 
syndrome) consists of a constellation of metabolic abnormalities that 
confer increased risk of cardiovascular disease (CVD) and diabetes 
mellitus (DM). Diagnosis of the metabolic syndrome requires the 
presence of at least three of the following five criteria26 
1. Elevated fasting plasma glucose levels (>110 mg/dL) 
2.  Visceral obesity (waist circumference >35 inches in women 
and 40 inches in men) 
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3.  Hypertension (>130/85 mm Hg) 
4.  Hypertriglyceridemia (>150 mg/dL)  
5.  Low high-density lipoprotein (HDL) cholesterol                       
(<40 mg/dL in men and <50 mg/dL in women) 
 
THYROID 
The thyroid (Greek thyreos, shield, plus eidos, form) consists of 
two lobes that are connected by an isthmus. It is located anterior to the 
trachea between the cricoid cartilage and the suprasternal notch. Four 
parathyroid glands, which produce parathyroid hormone are located 
posterior to each pole of the thyroid.27 
The normal thyroid gland secretes sufficient amounts of the thyroid 
hormones triiodothyronine (T3) and tetraiodothyronine (T4, thyroxine) to 
normalize growth and development, body temperature, and energy levels. 
Calcitonin, the second type of thyroid hormone, is important in the 
regulation of calcium metabolism.28 
 
BIOSYNTHESIS OF THYROID HORMONES27 
Iodide, ingested from food, water, or medication, is rapidly  
absorbed from intestine and enters an extracellular fluid pool. Transport 
of iodide into the thyroid gland is by an intrinsic follicle cell basement 
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membrane sodium/iodide symporter (NIS). At the apical cell membrane a 
second I- transport enzyme called pendrin is present. Iodide is oxidized 
by thyroidal peroxidase to iodine that rapidly iodinates tyrosine residues 
within the thyroglobulin molecule to form monoiodotyrosine (MIT) and 
diiodotyrosine (DIT). This process is called iodide organification.Two 
molecules of DIT combine within the thyroglobulin molecule to form            
L-thyroxine (T4). One molecule of MIT and one molecule of DIT 
combine to form T3. T4, T3, MIT, and DIT are released from 
thyroglobulin by exocytosis and proteolysis of thyroglobulin at the apical 
colloid border. Most of the hormone released is thyroxine. Most of the T3 
circulating in the blood is derived from peripheral metabolism of T4.  
Both hormones are bound to plasma proteins, including thyroxine 
binding globulin (TBG); transthyretin (TTR); and albumin. The plasma 
binding proteins increase the pool of circulating hormone, delay hormone 
clearance, and may modulate hormone delivery to selected tissue sites. 
 
DEIODINASES27 
T4 is converted to T3 by the deiodinase enzyme. 
¶ Type I deiodinase, which is located primarily in thyroid, liver, 
and kidney, has a relatively low affinity for T4. 
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¶ ype II deiodinase has a higher affinity for T4 and is found 
primarily in the pituitary gland, brain, brown fat, and thyroid 
gland. 
¶ Type III deiodinase inactivates T4 and T3 and is the most 
important source of reverse T3 (r T3) 
 
PHYSIOLOGICAL EFFECTS OF THYROID HORMONES29 
ª Heart: Increases number of β adrenergic receptors. Enhances 
response to catecholamines 
ª Adipose tissue: Stimulate lipolysis  
ª Muscle: Increases protein breakdown 
ª Bone: Promote growth and development 
ª Nervous system: Promote normal brain development 
ª Gut: Increases carbohydrate absorption 
ª Lipoprotein: Stimulate LDL receptors 
ª Others: Increases metabolic rate and oxygen consumption 
 
REGULATION OF THYROID AXIS27 
The thyroid axis is a classic example of an endocrine feedback 
loop. TRH stimulates pituitary production of TSH, which, in turn, 
stimulates thyroid hormone synthesis and secretion. Thyroid hormones 
feed back to inhibit TRH and TSH production. 
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EXOGENOUS AND ENDOGENOUS FACTORS SUPPRESSING 
TSH SECRETION30 
 
Dopamine antagonists, Somatostatin, Dobutamine, 
Glucocorticoids, Interleukins, TNF-α, Thyroid hormones and Phenytoin.  
FACTORS ASSOCIATED WITH ALTERED BINDING OF 
THYROXINE BY THYROXINE-BINDING GLOBULIN30 
Increased Binding 
Pregnancy, Oral contraceptives, Infectious hepatitis, Cirrhosis, 
HIV, Acute intermittent porphyria and Tamoxifen. 
Decreased Binding 
Androgens, Large doses of glucocorticoids, acromegaly, Nephrotic 
syndrome, Major systemic illness and Psychiatric illness. 
 
FACTORS ASSOCIATED WITH DECREASED CONVERSION 
OF T4 TO T330 
 
Fetal life, Caloric restriction, Hepatic disease, Major Systemic 
illness, Propylthiouracil, Glucocorticoids, Propranolol, Iodinated X-ray 
contrast agents, Amiodarone and Selenium deficiency. 
HYPOTHYROIDISM 
Hypothyroidism is the condition resulting from a lack of effects of 
thyroid hormones on body tissues.31 
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Symptoms 
Tiredness, weaknes, dry skin, feeling cold, hair loss, difficulty 
concentrating and poor memory, constipation, weight gain with poor 
appetite, dyspnea, hoarse voice, menorrhagia (later oligomenorrhea or 
amenorrhea), paresthesia and impaired hearing. 
 
Signs 
Dry coarse skin; cool peripheral extremity, puffy face, hands, and 
feet (myxedema), diffuse alopecia, bradycardia, peripheral edema, 
delayed tendon reflex relaxation, carpal tunnel syndrome and serous 
cavity effusions27 
 
METABOLIC ABNORMALITIES IN HYPOTHYROIDISM 
Hypothyroidism is associated with a reduction in glucose disposal 
to skeletal muscle and adipose tissue and also associated with reduced 
gluconeogenesis. The net effect of these influences is usually minimal on 
serum glucose levels. Degradation of insulin, is slowed and the sensitivity 
to exogenous insulin may be increased.32 Both the synthesis and the 
degradation of lipid are depressed in hypothyroidism with a net effect of 
accumulation of LDL and triglycerides. HDL concentrations and Plasma 
free fatty acid levels are decreased.33 
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SUBCLINICAL HYPOTHYROIDISM 
Defined as a low-normal free T4 but a slightly elevated serum TSH  
level. The TSH elevation in such patients is modest, with values typically 
between 4 and 15 mU/L.33 Rates of progression to overt hypothyroidism 
ranges from 3% to 8% per year, higher rates seen in individuals with 
initial TSH concentration greater than 10 mU/L and those with positive 
anti-TPO antibodies.34 The association of mild hypothyroidism with an 
increase in risk for atherosclerotic heart disease has been shown by some, 
but not others.35,36 
 
HYPERTHYROIDISM27 
Hyperthyroidism is a state when thyrotoxicosis occurs because of 
sustained over production of hormones by thyroid gland. 
 
Symptoms 
Heat intolerance and sweating, palpitation, fatigue and weakness, 
weight loss with increased appetite, diarrhea, polyuria, oligomenorrhea, 
and loss of libido. 
Signs 
Tachycardia; atrial fibrillation in the elderly, tremor, goiter, warm, 
moist skin, muscle weakness, proximal myopathy, lid retraction or lag 
and gynecomastia. 
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METABOLIC ABNORMALITIES IN HYPERTHYROIDISM 
Preexisting diabetes mellitus may be aggravated, one cause being 
accelerated turnover of insulin.37 Both lipogenesis and lipolysis are 
increased in thyrotoxicosis, but the net effect is lipolysis, as reflected by 
an increase in the plasma concentration of free fatty acids and glycerol 
and a decrease in serum cholesterol level.Triglyceride levels are usually 
slightly decreased.38 
 
SUBCLINICAL HYPERTHYROIDISM 
There are no signs of thyrotoxicosis but the serum TSH is subnormal 
despite normal serum free T4 concentration.37 Subclinical 
hyperthyroidism may accelerate bone loss in postmenopausal women39 
and increases the incidence of atrial arrhythmias including atrial 
fibrillation in elderly patients.31 
 
DIABETES AND THYROID DISEASES 
Diabetes mellitus and thyroid diseases are the two common 
endocrinopathies seen in the adult population. Insulin and thyroid 
hormones are intimately involved in cellular metabolism. Excess or 
deficit of either of these hormones could result in the functional 
derangement of the other.40 
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EFFECT OF DIABETES ON THYROID FUNCTION 
In euthyroid individuals with diabetes mellitus, the serum T3 
levels, basal TSH levels and TSH response to thyrotropin releasing 
hormone (TRH) may all be strongly influenced by the glycemic status.41 
Poorly controlled diabetes, both Type 1 and Type 2, may induce a “Low 
T3 state” characterized by low serum total and free T3 levels, increase in 
reverse T3 (r T3) but near normal serum T4 and TSH concentrations.42 
Low serum T3 is due to reduced peripheral conversion of thyroxine (T4) 
to tri-iodothyronine (T3) via 5’ monodeiodination reaction and may 
normalize with improvement in glycemic status but even with good 
diabetes control, the normal nocturnal TSH peak may not be restored in 
C-peptide negative patients.43 
 
EFFECT OF DIABETES MELLITUS ON THYROID DISEASES 
Dysthyroid optic neuropathy (DON) resulting in blindness is the 
most threatening complication of Graves’ orbitopathy (GO). It is due to 
the compression of optic nerve by enlarged extraocular muscles at the 
orbital apex. 
Incidence of DON in patients with diabetes mellitus is higher than 
that seen in control “GO” group and the recovery after treatment is also 
poor. This has been explained by reduced oxygenation of optic nerve in 
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diabetic patient owing to the vasculopathy making it more susceptible to 
the pressure effect.44 
 
EFFECT OF HYPERTHYROIDISM ON GLYCEMIC STATUS 
Graves disease is the commonest cause of hyperthyroidism. While 
Graves disease may be associated with type 1 diabetes in polyglandular 
autoimmune syndrome, thyrotoxicosis by itself is diabetogenic. Frank 
diabetes occurs in 2-3%, when hyperthyroidism develops in normal 
individuals. In known diabetic patients hyperthyroidism causes 
deterioration of glycemic control status.42 
These changes are due to alteration in following systems 
 
1. Gastrointestinal System 
In hyperthyroidism, there is accelerated gastric emptying, enhanced 
intestinal glucose absorption and an increase in portal venous blood 
flow.44 
 
2. Insulin Secretion 
Insulin secretion decreases in hyperthyroidism.45,46 Insulin 
clearance rate is reported to be increased by about 40%.47 Long term 
thyrotoxicosis has been shown to cause beta cell dysfunction resulting in 
poor insulin response to glucose.48 
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3. Endogenous Glucose Production 
In hyperthyroidism the endogenous glucose production is greatly 
increased by a variety of mechanisms: (a) there is an increase in the 
availability of gluconeogenic precursors( lactate, glutamine, alanine and 
FFA) stimulating hepatic gluconeogenesis;49 (b) Inhibition of glycogen 
synthesis;50 (c) Upregulation of GLUT-2 glucose transporters protein 
expression in the hepatocyte;51 (d) Increased secretion and exaggerated 
effects of glucagon and adrenaline on liver cells.49 
 
4. Glucose utilization 
In adipocytes isolated from rats, the sensitivity of glucose transport 
and utilization to insulin has been found to be normal, increased or 
decreased.45 In skeletal muscle, there is a preferential increase in glucose 
uptake and lactate formation . This is due to increase in GLUT-1 and 
GLUT-4 transporters52, increased glycogenolysis due to beta adrenergic 
stimulation49, increased activity of hexokinase and 5 
phosphofructokinase.53 
Thus the net effect of changes occurring at various levels such as 
gastrointestinal tract, beta cells, hepatocytes, adipocytes and skeletal 
muscles is hyperglycemia. 
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EFFECT OF HYPOTHYROIDISM ON GLYCEMIC STATUS 
In hypothyroidism, the synthesis and release of insulin is 
decreased.46 The rate of hepatic glucose output is decreased probably due 
to reduced gluconeogenesis. A post receptor defect has been proposed to 
explain the decrease in insulin stimulated glucose utilization in peripheral 
tissues.49 The net effect is an increased risk of recurrent hypoglycemia in 
a diabetic individual.54 
 
ASSOCIATION BETWEEN DIABETES MELLITUS AND 
THYROID DISORDERS 
 
Celani MF et al in their study found that abnormal TSH values in 
type 2 diabetic patients found before tight glycemic control reverted to 
normal values with adequate treatment of diabetes with OHA or insulin. 
They suggested that the diagnosis of thyroid dysfunction in type 2 
diabetes should be delayed until improvement of metabolic status.55 
Proces S et al in their study found that in diabetic patients TSH was 
lower than in non diabetic subjects. They concluded that besides known 
parameters such as age and drugs, thyroid function tests can also be 
altered in diabetes mellitus and obesity.56 
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Warren RE et al in their study found that serum thyrotropin (i.e. 
baseline TSH) is a better predictor of thyroid dysfunction than thyroid 
autoantibodies in people with diabetes.57 
Vondra K et al in their study found that prevalence of thyroid 
disease in diabetic patients is 2-3 times higher than in non diabetic 
subjects. It raises with age and is strongly influenced by female gender 
and autoimmune diabetes. They even recommended thyroid disease 
screening and diagnosis in patients with diabetes mellitus.58 
Abdel Rahman et al in their study found that overall prevalence of 
thyroid diseases was 12.5% in type 2 diabetes mellitus group. The study 
suggested that diabetic patients should be screened for asymptomatic 
thyroid dysfunction.59 
Perros P et al in their study found that the prevalence of thyroid 
disease was 13.4% in a randomly selected group of 1310 adult diabetic 
patients attending a diabetic clinic. They suggested that thyroid function 
should be screened annually in diabetic patients to detect asymptomatic 
thyroid dysfunction which is increased in frequency in a diabetic 
population.60 
Smithson MJ in his study found that the prevalence of thyroid 
disease (previously known and diagnosed as a result of screening) in the 
entire population of diabetic patients in his sample of 4300 general 
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practice patients was 10.8%. He concluded by suggesting that screening 
for thyroid disease should be considered in patients receiving diabetes 
care in community.61 
Zdrojewicz Z et al in their study found that there was no difference 
in thyroid gland function in patients with non insulin dependent diabetes 
mellitus (type 2) and different therapies have no influence on thyroid 
gland function.62 
Parr JH et al in their study found that improvement in long term 
metabolic control did not influence free thyroid hormone levels in well 
controlled and moderately-poor controlled diabetics taking insulin.63 
Chubb SA et al in their study found that none of those patients with 
type 2 diabetes diagnosed as subclinical hypothyroidism had overt 
hypothyroidism when restudied after 5 years. So they concluded that 
subclinical hypothyroidism is a common but incidental finding and 
routine screening of thyroid function in type 2 diabetes is questionable.64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS 
AND METHODS 
 
 
 
 
 25 
MATERIALS AND METHODS 
 
The present study titled "Thyroid Profile in Type 2 Diabetes 
Mellitus"was carried out in the Department of Medicine and in the 
Department of Diabetology, AGMGH, Trichy. 
¯ Study design: Cross sectional study. 
¯ Period of study:  January 2010 to October 2010 
¯ Materials: Questionnaire, BMI calculation, Blood pressure, FBS, 
PPBS, Blood Urea, Serum creatinine,ECG, Thyroid profile (FT3, 
FT4 and TSH 
¯ Study group: The study group included 100 persons with known 
type 2 diabetes  without known thyroid disorders attending the 
outpatient departments who met the inclusion criteria. 
 
Inclusion Criteria 
Known type 2 diabetes mellitus subjects who gave informed 
consent to participate in the study. 
Exclusion Criteria 
E Patients not willing for study 
E Patients with known thyroid disease 
E Patients with chronic renal failure and Diabetic nephropathy.  
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E Patients with acute illness (sepsis, acute MI, severe heart failure,   
recent admission in intensive care unit) 
E Patients with hepatic dysfunction 
E Patients with psychiatric illness. 
E Pregnancy 
E Patients on treatment with drugs interfering with thyroid function 
(amiodarone, propranolol, corticosteroids and oral contraceptives) 
All patients in the study group were selected without any bias for 
sex, duration, severity or control of diabetes. A thorough history was 
recorded with particular emphasis on symptoms of hypothyroidism and 
hyperthyroidism. The presence of associated illness like coronary artery 
disease, hypertension and cerebrovascular accident were noted. Family 
history regarding diabetes mellitus and treatment history of oral 
hypoglycaemics or insulin along with duration was also included. 
A thorough general and systemic examination was carried. 
 
BMI calculation 
Body mass index (BMI) is calculated with height and weight of the 
subject using the following formula. 
BMI = 2
weight(kg)
height(m )
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Blood sugar 
Both fasting and postprandial blood sugar are estimated by 
Trinder’s (Glucose oxidase) method and read at 505/670 nm. 
 
Renal function test 
The Blood Urea in this study was estimated using DAM method 
(Diacetyl Monoxime). Serum creatinine was estimated using Modified 
Jaffe’s method. 
 
Thyroid Profile 
Estimation done in fasting serum sample. 
Methods used: 
1. TSH - Ultrasensitive sandwich chemi luminescent immuno assay 
2. FT3 & FT4 - Competitive chemi luminescent immuno assay. 
 
 
DEFINITIONS 
Diabetes Mellitus 
The WHO in consultation with an expert committee of the 
American Diabetes Association has approved the following diagnostic 
criteria for Diabetes Mellitus,which was used to diagnose new cases. The 
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patients on antidiabetic therapy were also considered as having diabetes 
mellitus.  
Fasting: No caloric intake for atleast 8 hours.2-3 days of unrestricted 
carbohydrated diet prior to the test. No physical activities during the 
procedures.  
Systemic Hypertension (As per the JNC VII Guidelines): Subjects on 
medications for hypertension and those who had a systolic blood pressure 
of 140 mmHg and / or diastolic blood pressure 90 mmHg were 
considered to have hypertension. 
 
Diabetes mellitus is considered as Coronary Heart Disease equivalent.  
BMI (WHO criteria for Asian population): is used for classifying the 
subjects according to the weight status.  
BMI Group BMI (kg/m2) 
Underweight < 18.5 
Normal weight 18.5-24.9 
Overweight 25-29.9 
Obesity 30.0 
 
Thyroid profile 
Reference values: FT3 : 1.7-4.2 rg/ml  
FT4: 0.7- 1.8 hg/dl 
TSH: 0.35-5.5 mIU/ml 
 29 
v Overt hypothyroidism is defined as TSH >5.5 mIU/ml with FT4 
< 0.7 hg/dl. 
v Subclinical hypothyroidism is defined as  TSH > 5 mIU/ml with 
normal FT3 and FT4 levels  
v Overt hyperthyroidism is defined as TSH < 0.3 mIU/ml with 
FT4 > 1.8 hg/dl 
v Subclinical hyperthyroidism is defined as TSH < 0.3 mIU/ml 
with normal FT3 and FT4 levels 
 
 
 
 
 
 
 
 
 
 
 
RESULTS AND 
ANALYSIS 
 
 
 
 
 30 
RESULTS AND ANALYSIS 
 
The present study titled “Thyroid Profile in Type 2 Diabetes 
Mellitus” was undertaken in the Department of Medicine and Department 
of Diabetology, AGMGH, trichy over a period of 10 months from 
January 2010 to October 2010. 
The study sample included 100 type 2 diabetes patients in the 
outpatient department. Following were the observations: 
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Table-1 
Age Distribution of Cases 
 
Age Group (yrs) No. of cases Percentage 
Upto 40 24 24 
41-60 58 58 
61 & above 18 18 
 Total 100 100.0 
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Table-2 
Distribution of Cases According to Sex 
 
Sex No. of cases Percentage 
Male 52 52 
Female 48 48 
Total 100 100.0 
 
. 
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Table -3 
 Distribution According to Duration of Diabetes Mellitus 
 
Duration of DM No. of cases Percentage 
Upto 5 Years 74 74 
6 – 10 Years 20 20 
More than 10 
Years 6 6 
Total 100 100 
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Distribution According to Duration of Diabetes Mellitus 
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Table-4  
 Distribution According to Regularity of treatment 
 
Regularity of  
Treatment No. of cases Percentage 
Regular 82 82 
Irregular 18 18 
Total 100 100.0 
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Distribution According to Regularity of treatment 
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Table – 5  
Distribution according to Family history of Diabetes Mellitus 
 
 
Family H/O DM No. of cases Percentage 
Yes 44 44 
No 56 56 
Total 100 100.0 
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Distribution according to Family history of Diabetes Mellitus 
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Table-6 
Distribution of cases according to BMI 
 
BMI Group 
(Kg/m2) No. of cases Percentage 
< 18.5 2 2 
18.5-24.9 18 18 
25 – 29.9 56 56 
Above 30 24 24 
Total 100 100.0 
 
Among the study population, 80% (80/100) were overweight and 
obese; 18% (18/100 ) had normal BMI. 
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Distribution of cases according to BMI 
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Table-7 
Distribution of Cases according to Abnormal thyroid profile 
 
Thyroid Function Number Percentage 
With normal thyroid 
profile 80 80 
With abnormal 
thyroid profile 20 20 
Total 100 100.0 
 
 
 44 
 
Distribution of Cases according to Abnormal thyroid profile 
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Table – 8 
Distribution of thyroid diseases 
 
Thyroid Profile No. of cases Percentage 
Normal 80 80 
Overt 
hyporthyroidism 3 3 
Subclinical 
hypothyroidism 11 11 
Over 
hyperthyroidism 1 1 
Subclinical 
hyper thyroidism 5 5 
Total 100 100.0 
 
The above table shows that 11% (11/100) of the patients had report 
suggestive of sub clinical hypothyroidism and 5% (5/100) of the patients 
had report suggestive of sub clinical hyperthyroidism. 
 
 46 
 
Distribution of thyroid diseases 
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DISTRIBUTION OF THYROID DISEASE IN THE POPULATION STUDIED 
 
NO NAME AGE/SEX YEARS 
FT3 
rg/ml 
FT4 
hg/dl 
TSH 
mIU/ml DIAGNOSIS 
1 Mr. Palanisamy 60/M 3.2 1.4 7.92 Subclinical hypothyroidism 
2 Mrs. Vasanthakumari 40/F 2.72 0.86 6.24 Subclinical hypothyroidism 
3 Mrs. Rajalakshmi 57/F 2.57 0.86 5.924 Subclinical hypothyroidism 
4 Mrs. Maanvizhi  46/F 2.81 1.2 5.938 Subclinical hypothyroidism 
5 Mr. Periyasamy  72/M 2.18 1.05 9.696 Subclinical hypothyroidism 
6 Mr. Annadurai  36/M 2.99 1.07 6.139 Subclinical hypothyroidism 
7 Mr. Kumar  53/M 2.69 0.85 9.611 Subclinical hypothyroidism 
8 Mrs. Shanmugarani  52/F 2.61 1.0 5.671 Subclinical hypothyroidism 
9 Mr.Maniyan  59/M 3.15 1.1 6.434 Subclinical hypothyroidism 
10 Mrs.Velmani 45/F 2.6 0.88 8.9 Subclinical hypothyroidism 
11 Mrs.Amsavalli  42/F 2.79 0.65 9.8 Subclinical hypothyroidism 
12 Mrs.Dhanushkodi 50/F 2.59 0.63 38.43 Overt hypothyroidism 
13 Mrs.Meenambigai 42/F 1.5 0.46 > 150 Overt hypothyroidism 
14 Mrs.Pushpa 56/F 2.33 0.71 35.64 Overt hypothyroidism 
15 Mrs.Tamilarasi 40/F 3.2 1.88 0.28 Subclinical hyperthyroidism 
16 Mrs.Uma maheswari 40/F 3.62 1.8 <0.01 Subclinical hyperthyroidism 
17 Mrs.Jaya 39/F 3.17 1.3 0.205 Subclinical hyperthyroidism 
18 Mrs.Suganthi 37/F 2.66 1.11 0.21 Subclinical hyperthyroidism 
19 Mrs.Latha 35/F 3.03 1.32 0.172 Subclinical hyperthyroidism 
20 Mr.Gunasekaran 40/M 8.41 4.72 0.015 Overt hyperthyroidism 
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Table – 9 
Abnormal thyroid profile Vs Age group 
 
Abnormal thyroid profile Agegroup(yrs)  No Yes Total 
count 16 8 24 
% with abnormal 
thyroid profile 20 40  Up to 40 
% of total 16 8 24 
count 47 11 58 
% with abnormal 
thyroid profile 58.75 55  41-60 
% of total 47 11 58 
count 17 1 18 
% with abnormal 
thyroid profile 21.25 5  >60 
% of total 17 1 18 
count 80 20 100 
% with abnormal 
thyroid profile 100 100  Total 
% of total 80 20 100 
 
P> 0.05  Not significant 
Out of 20 patients with abnormal thyroid profile, 1patient (5%) were 
found to be of age 61years and more, 11 (55%) were found to be of age 
between 41-60 years and 8 (40%) were found to be 40 years or less. 
Compared with normal thyroid profile group it has no statistical 
significance. 
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Abnormal thyroid profile Vs Age group 
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Table-10 
Abnormal thyroid profile Vs Sex 
 
Abnormal thyroid profile 
Sex 
 No Yes Total 
count 46 6 52 
% with abnormal 
thyroid profile 57.5 30  Male 
% of total 46 6 52 
count 34 14 48 
% with abnormal 
thyroid profile 42.5 70  Female 
% of total 34 14 48 
count 80 20 100 
% with abnormal 
thyroid profile 100 100  Total 
% of total 80 20 100 
                       
P <0.05 Significant 
Out of 20  patients with abnormal thyroid profile, 30%(6) were 
males and 70%(14) were females. Compared with normal thyroid profile 
group, this is statistically significant . 
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Abnormal thyroid profile Vs Sex 
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Table-11 
 
Abnormal thyroid profile Vs Duration of Diabetes 
 
Abnormal thyroid profile 
Duration (yrs) 
 No Yes Total 
count 58 16 74 
% with abnormal 
thyroid profile 72.5 80  Up to 5 
% of total 58 16 74 
count 17 3 20 
% with abnormal 
thyroid profile 21.25 15  6-10 
% of total 17 3 20 
count 5 1 6 
% with abnormal 
thyroid profile 6.25 5  >10 
% of total 5 1 6 
count 80 20 100 
% with abnormal 
thyroid profile 100 100  Total 
% of total 80 20 100 
 
p>0.05 not Significant 
Among the 20 patients with abnormal thyroid profile, 5%(1) had 
Diabetes more than 10 years, 15%(3) had duration between 6-10 years 
and 80%(16) had Diabetes 5 years or less. It is not  statistically 
significant. 
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Abnormal thyroid profile Vs Duration of Diabetes 
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Table-12 
Abnormal thyroid profile Vs Family history of Diabetes 
 
Abnormal thyroid profile Family history 
of DM  No Yes Total 
count 26 18 44 
% with abnormal 
thyroid profile 32.5 90  YES 
% of total 26 18 44 
count 54 2 56 
% with abnormal 
thyroid profile 67.5 10  NO 
% of total 54 2 44 
count 80 20 100 
% with abnormal 
thyroid profile 100 100  Total 
% of total 80 20 100 
 
 P < 0.05 Significant 
18 (90%) out of 20 patients with thyroid abnormality had family 
history of diabetes, but only   32.5%(26) of normal thyroid group had it. 
Statistically the difference is significant. 
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Abnormal thyroid profile Vs Family history of Diabetes 
 
 
32.5
67.5
90
10
0
10
20
30
40
50
60
70
80
90
100
Pe
rc
en
ta
ge
Normal Abnormal
Family History DM
Yes No
 56 
Table-13 
 
Abnormal Thyroid Profile Vs BMI 
 
Abnormal thyroid profile 
BMI 
 Yes No Percentage 
count 1 1  
<18.5 
% of total 5 5 5 
count 4 14  
18.5-24.9 
% of total 20 17.5 20 
count 9 47  
25-29.9 
% of total 45 58.75 45 
count 6 18  
>30 
% of total 30 22.5 30 
 
p >0.05 Not significant 
Out of 20  persons with abnormal thyroid profile, 75%(15) were 
overweight and obese. Compared with normal thyroid profile group this 
is not statistically significant. 
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Distribution of Abnormal thyroid profile according to BMI  
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DISCUSSION 
 
Diabetes mellitus is the most common endocrine disorder which 
involves multiple organ systems and leads to significant morbidity and 
mortality due to accompanying complications. Thyroid diseases are also a 
common endocrinopathy seen in the adult population. Thyroid hormones 
are intimately involved in cellular metabolism. Thus excess or deficit of 
either insulin or thyroid hormone could result in the functional 
derangement of the cellular metabolism. 
In the present study patients of diabetes mellitus were taken from 
Diabetic Outpatient Department, AGMGH, Trichy, over a period of 10 
months from January 2010 to October 2010 and they were evaluated for 
altered thyroid profile. 
 
AGE DISTRIBUTION 
In the present study of 100 type 2 diabetic patients, 24 patients 
(24%) were up to 40 years, 58 patients (58%) were between 41-60 years 
and 18 patients (18%) were 61 years or more. This shows that the disease 
was more prevalent between 41-60 years of age.  
This observation was similar to WHO report which predicts that 
while the main increase in diabetes would be in the > 65 year age group 
 59 
in the developed countries, in India and developing countries the highest 
increase would occur in the age group of 45-65 year of age group.65 
This observation is also similar to Kapur et al, who reported that 
maximum number of cases were diagnosed between 40 and 59 year of 
age with no significant difference between the genders.66 
 
GENDER DISTRIBUTION 
In the present study 52% (52 nos) of the studied population were 
males and 48% (48 nos) were females. Male to Female ratio was 1.08:1.  
This observation was similar to Jali et al68 and Flatau E et al69 who 
reported that diabetes was more prevalent in men than in women.  
This is in contrast to Arthur M. Michalek et al who reported that 
prevalence of diabetes among women was higher than in men.67 Sample 
size in our study is too small. This might have affected the results. 
 
DURATION OF DIABETES MELLITUS 
In the present study, majority of cases that is 74% (74/100) had 
durationof diabetes up to 5 years, 20% (20/100) of patients had duration 
between 6-10 years and 6% (6/100) of patients had duration of illness 
more than 10 years.Majority of people are in the age group between 41 to 
60 yrs and have duration of disease less than 5 years. 
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FAMILY HISTORY OF DIABETES MELLITUS 
In the present study, 44% (44nos) of patients had family history of 
diabetes and the remaining 56% (56nos) had no family history. 
This study is similar to that of Tattersal and Fojans70 and 
Vishwanthan.71 Vishwanthan et al conducted a study among 107 subjects. 
Out of 73 subjects who gave positive family history diabetes, 19 subjects 
(26%) later developed diabetes. 
 
REGULARITY OF TREATMENT 
In the present study, out of 100 subjects of the study group 82% 
(82/100) were on regular treatment and 18% (18/100) were irregular.  
Asha et al observed that 97% of type 2 diabetics were on 
antidiabetic agents and most were using them irregularly.72  
Kaur et al observed that oral anti diabetic drug compliance rate was 
62.9% in diabetic population.73 The difference in our study may be due to 
small sample size.  
BMI 
Among the study population, 80%(80/100) were overweight and 
obese; 18%(18/100) had normal BMI. Mc Larty et al reported that 
prevalence of IGT in subjects of all age group increased with rising 
BMI.74 
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Yon Gik et al reported that the prevalence of diabetes mellitus and 
IGT increased with rising BMI and with increase in WHR.75 Both these 
studies support our findings. 
 
ABNORMAL THYROID PROFILE 
In the present study, 20% (20) of the total 100 patients with  
diabetes mellitus had abnormal thyroid profile. The present study is 
similar to Abdel-Rahman et al who in his study of 908 type 2 diabetic 
patients found that the prevalence of thyroid disease was 12.5%, 6.6% of 
whom were newly diagnosed and 5.9% had known thyroid dysfunction. 
The prevalence of thyroid disease in the non diabetic control group was 
6.6%.59 
Chubb et al in a cross-sectional study of 420 patients with type 2 
diabetes mellitus found that 8.6% of patients had subclinical 
hypothyroidism.64 
Smithson M J in his study found that the prevalence of thyroid 
disease in the entire population of diabetic patients registered in the 
general practice was 10.8%. In the control group of non diabetics, the 
prevalence was 6.6%.61 
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D.H. Akbar et al in their study of 100 type 2 diabetics found that 
the prevalence of thyroid dysfunction was 16% and in control group of 
non diabetics, it was 7%.76 
Zdrojewicz et al in their study of 75 diabetic patients found that 
there was no differences in thyroid gland function between patients with 
type 2 diabetes mellitus and non diabetics. This study contradicts our 
findings.62 
 
DISTRIBUTION OF THYROID ABNORMALITIES 
In the present study, 11% (11) of the patients had report suggestive 
of sub clinical hypothyroidism and 5% (5) of the patients had report 
suggestive of sub clinical hyperthyroidism. This study was similar to 
Abdel-Rahman et al who in their study of 908 type 2 diabetic patients 
found that 10.3% of patients had hypothyroidism (overt and sub clinical) 
and 1.7% of patients had hyperthyroidism (overt and sub clinical).59  
Smithson et al in their study of 233 diabetes mellitus patients found 
that 11 patients were found to have undiagnosed thyroid disease, out of 
which 9 were having hypothyroidism (overt and sub clinical) and 2 were 
having hyperthyroidism (overt and sub clinical).61 
Celani MF et al in their study of 290 type 2 diabetes mellitus 
patients found that 91 patients(31.4%) had abnormal TSH concentrations 
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out of which 48.3% had subclinical hypothyroidism, 24.2% had subclinicl 
hyperthyroidism, 23.1% had overt hypothyroidism and 4.4% had overt 
hyperthyroidism.55 
In the present study, diabetic patients, when compared with the 
control group of normal patients in Whickham Study77 and a 20 years 
follow-up of Whickham survey by Vanderpump MP et al78 shows that the 
prevalence of altered thyroid profile in the study group is significant 
(p=0.0064). 
 
The presence of altered thyroid profile in diabetic patients may be 
due to the fact that: 
In euthyroid individuals with diabetes mellitus, the serum T3 
levels, basal TSH levels and TSH response to thyrotropin releasing 
hormone (TRH) may all be strongly influenced by the glycemic status.41 
Poorly controlled diabetes may also result in impaired TSH 
response to TRH or loss of normal nocturnal TSH peak.43 It may be 
related to older age of the type 2 DM patients.64 
 
SIGNIFICANCE OF AGE IN PATIENTS WITH ABNORMAL 
THYROID PROFILE 
Among the patients with abnormal thyroid profile, each 45% (9/20) 
of patients were found to be of age 61 and more and 40 or less. 55% 
(11/20) were found to be of age between 41-60 years. Though there is 
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difference, when compared between patients with normal and abnormal 
thyroid profile it has no significance (p = 0.987) 
Vondra et al in his study found that thyroid diseases in diabetic 
patients is 2-3 times higher than in nondiabetic subjects; it raises with 
age, and is strongly influenced by female gender and autoimmune 
diabetes. This also contradicts with our findings.58 
 
ANALYSIS OF SEX DISTRIBUTION IN CASES WITH 
ABNORMAL THYROID PROFILE 
 
In the present study 85.7% (12/14) patients were found to be 
female compared to 14.3% (2/12) male in the group with abnormal 
thyroid profile. 
Compared between patients with normal and abnormal thyroid 
profile this is statistically significant (p=0.031). 
Celani MF et al, Arthur M. Michalek et al and Abdel-Rahman et al in 
their study found that the prevalence of thyroid dysfunction was 
significantly higher in the female than in the male diabetic patients.55,59,67 
Also Vondra et al and Cardoso et al found significant correlation 
between female gender and altered thyroid profile.58,79 
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ANALYSIS OF BMI IN CASES WITH NORMAL AND 
ABNORMAL THYROID PROFILE 
 
Out of 20 patients with abnormal thyroid profile, 45% (9/20) were 
overweight and 30% (6/20) were obese. There was no significant 
correlation between BMI and abnormal thyroid profile (p > 0.05). 
Fan W et al observed in their study that obese individuals have 
normal levels of thyroxine(T4) and thyroid stimulating hormone(TSH) 
but, increased levels of triiodothyronin(T3) in a minority of subjects.81 
The findings contradict with Process et al who in their study found that 
besides known parameters such as age and drugs, thyroid-function tests 
can also be altered by diabetes mellitus and obesity.55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
 
 66 
SUMMARY 
 
This study aimed at estimating the prevalence of thyroid 
dysfunction in type 2 Diabetes mellitus patients and also to find out it’s 
correlation with various risk factors. The study sample included 100 type 
2 diabetic patients presented in the outpatients department. Each patient 
was assessed clinically and by laboratory investigations. 
Primary observations regarding thyroid profile in patients with type 
2 diabetes mellitus. In the present study, 20%(20 nos) of patients with 
type 2 diabetes mellitus had abnormal thyroid profile. 
In patients with abnormal thyroid profile(20 nos), most common 
abnormality was subclinical hypothyroidism(55%) followed by 
subclinical hyperthyroidism(25%). 
Our study showed significant correlation between abnormal thyroid 
profile and gender, duration of diabetes and family history of diabetes.  
In persons with abnormal thyroid profile, 70% were females and 
30% were males. This is statistically significant. The prevalence of 
thyroid abnormalities is more common in females than in males. 
No significant correlation was found between altered thyroid 
profile and age, type of treatment, SHT and BMI. 
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Additional observations in the study group of type 2 diabetes 
mellitus subjects: 
In the present study, patients ranged from 35 to 79 years of age. 
Maximum number of patients were in the age group between 41 to 60yrs 
(58%). 
Majority (82%) of patients were on regular treatment and 18% 
were on irregular treatment. 
44% patients were having family history of diabetes mellitus and 
56% had no family history. 
Majority (80%) of the diabetic patients were overweight and obese. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
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CONCLUSION 
 
¨ Prevalence of thyroid dysfunction is more common among type 2 
diabetes mellitus patients than in general population.  
¨ Prevalence of thyroid dysfunction in patients with type 2 diabetes 
mellitus is higher in females than in males 
¨ There is no significant correlation between age, duration of 
diabetes, family history of diabetes and BMI. 
¨ Routine screening for thyroid dysfunction in type 2 diabetes 
mellitus patients may be justified especially in females because the 
progression to overt thyroid dysfunction is associated with 
significant morbidity including the adverse effects on glycemic 
control, lipid profile, bone mineral density and cardiovascular 
events. 
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LIMITATIONS 
· Study population was small. 
· Associated thyroid autoimmunity was not evaluated due to 
constraints.So it was not able to refine the spectrum of thyroid 
dysfunction in type 2 diabetics. 
· Follow up study was not done. So the natural history of subclinical 
thyroid dysfunction and its effect on various parameters could not 
be assessed. 
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RECOMMENDATIONS 
Biochemical tests of thyroid functions are readily available and 
relatively inexpensive. So, a baseline thyroid function test to be done in 
all type 2 diabetic patients at first visit especially in females. 
Longitudinal studies are needed to find out the incidence of thyroid 
dysfunction in type 2 diabetes mellitus patients and to determine the need 
of regular screening for thyroid dysfunction during follow up and its cost 
effectiveness. 
Follow up thyroid function test to be done to assess the progression 
of subclinical thyroid dysfunction in type 2 diabetics because of 
associated morbidity of overt thyroid dysfunction in these patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROFORMA 
DEPARTMENT OF MEDICINE 
K.A.P.VISHWANATHAM  GOVT. MEDICAL COLLEGE, 
TRICHY 
 
PROFORMA 
STUDY OF THYROID PROFILE IN TYPE 2  DIABETES 
MELLITUS 
 
Name    :   Age/Sex: 
Address   : 
Occupation   : 
Presenting Complaints : 
Tiredness                            Dry Skin               
muscle cramps                        Decreased sweating                      
Insomnia                                       Somnolence 
Poor Appetite                              Myalgia/Arthralgia 
Weight Gain/Weight Loss            Breathlessness 
Cold Intolerance                            Swollen Limb 
Constipation                                  Paresthesia 
Change in Voice                            Impaired Hearing 
Menstrual Irregularities                 Infertility/Abortion 
Libido                                           Poor Memory /Difficulty  
                                                      in concentration                                  
Behavioral Changes                       Tremors 
Palpitations                                    Irritability 
Past history   
HT/ Others    : 
IHD     : 
 
DIABETIC HISTORY 
Duration of diabetes  : 
Diabetic Status    : 
 
FAMILY HISTORY 
Hypothyroidism                        Goiter 
 
PERSONAL HISTORY 
Diet         :                                      
Menstrual History   : 
 
TREATMENT HISTORY 
OAD     : 
Insulin     : 
 
GENERAL EXAMINATION 
Height     : 
Weight    : 
BMI      : 
Pallor                    Icterus                  Xanthelasma              Madarosis 
Pulse                     Peripheral Pulsation 
B. P.  
Skin   : Cold/Coarse/Moist/Dry/Yellowish Discoloration 
Edema                 
Facial Puffiness  
Thyroid Gland : Normal/Enlarged 
 
SYSTEMIC EXAMINATION 
C. V. S.  : 
R. S.   : 
P/A   :  
C. N. S.  : 
 
INVESTIGATIONS 
Hb (gm%)  :  
FBS   : 
PPBS   : 
B. Urea  : 
Sr. Creatinine : 
ECG   : 
 
THYROID PROFILE 
FT3    : 
FT4    : 
TSH   : 
 
 
 
 
REMARK: 
                                                                    Signature of the guide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
MASTER CHART 
S. No Name Age/sex 
Duration 
of diabetes 
(Years) 
Regularity 
of 
treatment 
Family 
history 
BMI 
kg/m2 
FT3 
rg/ml 
FT4 
hg/dl 
TSH 
mIU/ml 
1.  Mr. Rangasamy 38/M 1Y Reg YES 24.73 1.86 0.78 4.18 
2.  Mrs. Moushika beevi 51/F 15Y Irreg YES 31.04 3.2 1.23 2.62 
3.  Mrs. Nashini begum 39/F 4Y Reg NO 23.37 2.88 1.29 1.88 
4.  Mrs. Pappa 48/F 1.5Y Reg NO 23.61 1.19 0.81 3.32 
5.  Mrs. Dhanushkodi 50/F 2/12Y Reg YES 30.43 2.59 0.63 38.43 
6.  Mrs. Meharunisha 47/F 3/12Y Reg NO 27.16 2.93 1.02 2.03 
7.  Mrs. Manimegalai 53/F 5Y Reg YES 35.2 2.5 0.7 4.73 
8.  Mr. Ismail 50/M 3Y Reg YES 27.63 3.65 0.97 2.45 
9.  Mrs. Andal 60/F 1.5Y Reg YES 31.34 3.12 0.89 0.41 
10.  Mrs. Parvathy 50/F 4/12Y Reg NO 35.55 2.42 0.79 1.95 
11.  Mrs. Selvi 38/F 3/12Y Reg YES 28.81 2.89 1.19 3.24 
12.  Mr. Prabakaran 47/M 4/12Y Reg NO 29.09 2 1.08 3.66 
13.  Mrs. Kairunisha 37/F 2/12Y Reg YES 28.22 2.94 1.2 3.24 
14.  Mr. Palanisamy 60/M 10Y Irreg NO 26.7 3.2 1.4 7.92 
15.  Mrs. Elisa 60/F 3Y Reg NO 25.96 2.42 1.26 0.34 
16.  Mr. Gopal 65/M 6Y Irreg NO 32 2.51 1.11 0.44 
17.  Mrs. Meenambigai 42/F 6/12Y Reg YES 33.77 1.5 0.46 >150 
18.  Mrs. Vasanthakumari 40/F 2 Y Reg NO 30.8 2.72 0.86 6.24 
19.  Mrs. Nagalakshmi 43/F 3.5Y Reg YES 30.08 2.76 1.35 3.4 
20.  Mrs. Tamilarasi 40/F 6.5Y Reg NO 25.68 3.2 1.88 0.28 
21.  Mrs. Sethu 45/F 2Y Reg NO 30.01 3.49 1.21 1.75 
22.  Mrs. Rajalakshmi 57/F 3Y Reg YES 28.57 2.57 0.86 5.924 
23.  Mrs. Maanvizhi 46/F 4Y Reg NO 26.47 2.81 1.2 5.938 
24.  Mr. Periyasamy 72/M 11Y Irreg YES 22.03 2.18 1.05 9.696 
25.  Mr. Annadurai 36/M 1Y Reg YES 23.43 2.99 1.07 6.139 
26.  Mrs. Uma mageswari 40/F 2Y Reg NO 25.2 3.62 1.8 <0.01 
27.  Mr. Kumar 53/M 3Y Reg YES 25.55 2.69 0.85 9.611 
28.  Mrs. Pushpa 56/F 3Y Reg NO 27.11 2.33 0.71 35.64 
29.  Mrs. Shanmugarani 52/F 5Y Reg YES 25.8 2.61 1 5.671 
30.  Mr. Maniyan 59/M 5Y Reg NO 27.68 3.15 1.1 6.434 
31.  Mrs. Sunathbee 40/F 1.5Y Irreg YES 30.54 2.51 1.01 1.56 
32.  Mrs. Velmani 45/F 10Y Reg NO 30.91 2.6 0.88 8.9 
33.  Mr. Abdulhaleem 45/M 5Y Reg YES 31.34 2.4 1.02 2.45 
34.  Mrs. Amsavalli 42/F 1Y Reg NO 30.8 2.79 0.65 9.81 
35.  Mrs. Ramu 55/F 5Y Reg YES 30.28 2.43 0.91 1.17 
36.  Mr. Gunasekaran 40/M 1Y Irreg NO 30.91 8.41 4.72 0.015 
37.  Mr. Santhanam 42/M 1Y Reg YES 31.95 1.54 1.11 1.246 
38.  Mrs. Nandhini 35/F 1Y Reg NO 24.77 1.9 1.54 2.864 
39.  Mr. Ramaiya 75/M 12Y Reg YES 24.03 2.34 0.9 1.559 
40.  Mr. Duraisamy 68/M 16Y Irreg YES 27.34 4.11 0.79 1.673 
41.  Mrs. Jaya 40/F 1.5Y Reg YES 26.66 3.45 0.98 3.057 
42.  Mrs. Kalyani 60/F 5Y Reg NO 32.23 2.43 1.45 0.505 
43.  Mrs. Valli 49/F 2Y Reg NO 27.94 1.78 1.78 0.802 
44.  Mrs. Sumathy 36/F 1Y Reg NO 29.09 2.67 1.43 5.173 
45.  Mrs. Suryapraba 49/F 3Y Reg NO 26.37 3.66 1.22 1.887 
46.  Mr. Ponnusamy 56/M 3Y Reg YES 29.29 3.76 1.04 1.52 
47.  Mr. Santhanasamy 45/M 2Y Irreg NO 27.23 2.54 0.71 1.844 
48.  Mr. Murugan 40/M 1Y Reg NO 29.13 1.97 0.86 0.728 
49.  Mrs. Kaliammal 48/F 3Y Reg YES 35.2 1.76 1.76 1.651 
50.  Mr. Sundarajan 64/M 7Y Reg NO 30.46 1.99 1.33 4.914 
51.  Mr. Palanisamy 41/M 1Y Reg YES 30.04 2.3 1.66 1.705 
52.  Mr. Ramkumar 35/M 1Y Irreg NO 29.38 1.89 1.8 1.247 
53.  Mr. Bala 62/M 8Y Reg NO 25.4 1.97 1.67 2.562 
54.  Mr. Veeramuthu 79/M 10Y Irreg YES 27.26 3.76 1.32 0.812 
55.  Mrs. Selvamani 50/F 2Y Reg NO 26.69 2.89 0.85 1.534 
56.  Mr. Senthilkumar 40/M 1.5Y Reg NO 26.45 2.34 0.95 3.218 
57.  Mrs. Papathy 49/F 3Y Reg YES 27.23 2.19 1.39 2.849 
58.  Mr. Abdulmalik 65/M 5Y Irreg NO 26.95 3.13 1.67 4.389 
59.  Mrs. Lalitha 50/F 2.5Y Reg YES 25.1 1.88 1.55 1.658 
60.  Mr. Somasundaram 50/M 2Y Irreg YES 23.61 1.99 1.79 1.636 
61.  Mr. Arokyasamy 65/M 6.5Y Reg YES 27.81 2.76 0.92 3.609 
62.  Mrs. Leelavathy 57/F 3.5Y Reg YES 29.51 2.88 1.56 1.927 
63.  Mrs. Kulanthaithersa 60/F 2Y Reg NO 24.44 3.46 1.68 4.289 
64.  Mr. Syed rasool 65/M 7Y Reg NO 31.44 3.87 1.76 2.79 
65.  Mrs. Vaidehi 58/F 2Y Irreg YES 25.64 2.1 1.51 1.525 
66.  Mrs. Shanmugavalli 36/F 2Y Reg YES 22.86 2.71 1.59 1.101 
67.  Mr. Gunasekaran 60/M 6Y Reg NO 26.02 3.03 0.74 1.346 
68.  Mr. Vetrivel 55/M 2Y Irreg YES 26.39 4.01 0.93 2.51 
69.  Mr. Alagappan 77/M 8Y Reg YES 24.55 2.38 1.49 1.819 
70.  Mr. Manikam 62/M 5Y Irreg YES 25.19 2.81 1.75 3.238 
71.  Mrs. Jaya 39/F 1Y Reg NO 24.24 3.17 1.3 0.205 
72.  Mr. Tamilarasan 50/M 2Y Reg NO 26.03 3.05 1.49 3.932 
73.  Mr. Muthurathnam 72/M 13Y Reg NO 29.67 3.17 1.68 5.052 
74.  Mr. Ramesh 37/M 2Y Reg YES 29.96 3.13 1.46 3.093 
75.  Mr. Velu 56/M 6Y Reg NO 29.27 2.31 0.96 1.469 
76.  Mrs. Kursheed 52/F 6Y Irreg NO 30.1 3.09 1.8 2.885 
77.  Mr. Savarimuthu 66/M 5.5Y Reg YES 26.89 2.9 1.48 3.371 
78.  Mr. Murugesan 43/M 1Y Reg NO 18.32 1.96 1.62 2.227 
79.  Mr. Rajagopal 58/M 6Y Reg NO 27.18 1.81 1.04 1.993 
80.  Mrs. Parveen 35/F 1Y Reg NO 28.93 3.79 1.02 1.361 
81.  Mrs. Suganthi 37/F 1Y Reg NO 23.01 2.66 1.11 0.21 
82.  Mrs. Meenakshi 50/F 2Y Reg NO 31.04 3.54 1.3 5.178 
83.  Mrs. Latha 35/F 1Y Irreg YES 18.14 3.03 1.32 0.172 
84.  Mr. Vijaykumar 53/M 2.5Y Reg NO 27.84 2.67 1.37 1.628 
85.  Mr. Arokyasamy 62/M 7Y Reg NO 27.51 2.9 1.08 3.86 
86.  Mr. Sankar 50/M 2Y Reg NO 27.14 2.77 1.69 1.785 
87.  Mr. Selvaraj 48/M 5Y Reg NO 28.65 3.8 1.67 2.189 
88.  Mrs. Mahalakshmi 60/F 6Y Reg YES 28.76 3.56 1.66 1.526 
89.  Mr. Arokyadas 42/M 4Y Reg NO 29.29 2.78 1.03 4.224 
90.  Mr. Velu 64/M 6.5Y Reg NO 26.72 2.21 1.18 1.407 
91.  Mr. Kandasamy 63/M 6Y Reg NO 25.97 2.69 1.31 3.764 
92.  Mrs. Mallika 51/F 3Y Reg NO 28.9 2.98 1.06 0.918 
93.  Mr. Arumugam 52/M 4.5Y Reg YES 24.03 3.69 1.18 1.125 
94.  Mr. Selvam 35/M 1Y Reg NO 21.63 3.23 1.37 3.58 
95.  Mr. Rajendran 52/M 3Y Irreg NO 20.07 2.77 1.58 1.673 
96.  Mrs. Senbagavalli 75/F 12Y Reg YES 27.97 2.18 1.77 3.899 
97.  Mr. Pandurangan 56/M 6Y Reg NO 22.97 2.94 1.59 2.283 
98.  Mr. Muthukrishnan 56/M 3Y Reg YES 25.1 3.22 1.03 2.407 
99.  Mrs. Lakshmi 50/F 2Y Reg NO 25.72 1.94 1.64 1.851 
100.  Mr. Senthil 35/M 1.5Y Reg YES 19.1 2.53 1.72 1.49 
 
 
